Prostate Cancer is the second most common cancer in men worldwide with one million new cases diagnosed globally each year. In Europe, it is estimated that over 70,000 men die from prostate cancer annually, making it the third leading cause of death from cancer in men.
Measurement of prostate specific-antigen (PSA) is commonly used as a screening tool for prostate cancer. However, high levels of PSA may be associated with other conditions affecting the prostate and may lead to unnecessary biopsies. Therefore, there is a need for additional diagnostic methods to avoid unneeded procedures.
In a successful feasibility study, Micromedic has shown that cells originated from the prostate were effectively collected in urine samples following prostate massage. The Company is now conducting an extended clinical study to further validate these findings.
Such urinary marker is envisioned to stratify patients with moderately elevated PSA levels, thus preventing unnecessary biopsies resulting from elevated PSA test.